Cogstate Welcomes Dr. Kaycee Sink as Chief Medical Officer
Cogstate, a prominent neuroscience technology firm, proudly announces the addition of Dr. Kaycee Sink to its leadership team as the Chief Medical Officer. Dr. Sink's vast experience and commitment to advancing Alzheimer's disease research position her to lead Cogstate's efforts in supporting clinical trials and enhancing the quality of data in this crucial area.
Dr. Sink's Expertise in Alzheimer's Disease
With extensive experience in developing drugs for Alzheimer's, Dr. Sink has been instrumental in overseeing global trials. Her role at Cogstate involves advising biopharmaceutical organizations on strategic trial designs, endpoint selection, and ensuring top-notch data quality for cognitive outcomes. This expertise will be fundamental as Cogstate navigates the complexities of clinical trials in neurodegenerative disorders.
Innovating Cognitive Assessments
In addition to her role in clinical trials, Dr. Sink will significantly contribute to the commercialization of cognitive assessment technologies. These innovations aim to facilitate quicker and more accurate diagnoses for healthcare providers and their patients, ensuring that effective treatments reach those in need as efficiently as possible.
Leadership Insight
The CEO of Cogstate, Brad O'Connor, expressed enthusiasm regarding Dr. Sink's appointment, highlighting the tremendous value her medical and research expertise brings to the company. This new leadership aims to accelerate the development of therapies for Alzheimer's disease, ultimately expanding treatment options and enhancing brain health awareness among aging populations.
Dr. Sink's Background
Previously, Dr. Sink held the position of Principal Medical Director in Neurodegeneration at Genentech, where she led various programs aimed at treating Alzheimer's and related disorders. Her strong academic background includes a stellar tenure as a Full Professor at Wake Forest School of Medicine, cementing her status as an expert in neurology and public health.
Commitment to Patient Care
Dr. Sink's approach to Alzheimer's research intertwines technology with compassionate care. As a board-certified specialist in Internal and Geriatric Medicine, she continues to see patients in the Memory Assessment Clinic, contributing to her deep understanding of the challenges faced by those with neurodegenerative disorders. Her dual role as a practitioner and researcher allows her to bring a unique perspective to the table.
About Cogstate
Cogstate Ltd (ASX: CGS) has been leading the charge in optimizing brain health assessments for over two decades. The company's innovative digital cognitive tests and eCOA solutions have supported researchers and clinicians worldwide, enhancing the development of new medicines and enabling faster clinical insights. With Dr. Sink's addition to the team, Cogstate is well-positioned to continue its vital work in neuroscience and mental health.
Rachel Colite
Cogstate
203-773-5010 x157
rcolite@cogstate.com
Frequently Asked Questions
Who is Dr. Kaycee Sink?
Dr. Kaycee Sink is the newly appointed Chief Medical Officer at Cogstate, with extensive experience in Alzheimer's disease research.
What role will Dr. Sink play at Cogstate?
She will lead clinical trial support and enhance cognitive assessment technologies to improve diagnoses and treatment processes.
Why is Dr. Sink's appointment significant?
Her expertise in drug development for Alzheimer's will help expedite trial processes and improve data quality in clinical studies.
What is Cogstate's mission?
Cogstate aims to optimize brain health assessments and advance neuroscience through innovative technological solutions.
How does Cogstate support healthcare providers?
Cogstate provides reliable cognitive tests and clinical solutions that enhance patient assessments and treatment options.
